In The Battle Against COVID-19, A Risk Of 'Vaccine Nationalism'

May 27, 2020
Originally published on May 27, 2020 10:57 am

The race to defeat the coronavirus can be viewed in two very distinct ways. One is based on international cooperation, with a vaccine treated as a "global public good." The other is competitive, a battle between nations that's being described as "vaccine nationalism."

Many are hoping for the former, but are seeing signs of the latter.

The main competition, on this and many other global issues, appears to be between the United States and China. Both President Trump and China's President Xi Jinping have faced criticism for their handling of the coronavirus outbreak. Success with a vaccine at home could make up for the earlier shortcomings.

"We're about to have an unprecedented battle over access to the vaccines, which will be far more challenging if we're in a U.S.-versus-China Cold War environment," said Ian Bremmer, president of the Eurasia Group, a political consulting firm.

Trump's Operation Warp Speed is designed to develop a COVID-19 vaccine for Americans as soon as possible, and with an eye on the November presidential election.

Last week, the U.S. government announced it was paying up to $1.2 billion to the drugmaker AstraZeneca to start work on a vaccine that could be ready as early as October, though there's not yet a vaccine that's been proved to be safe and effective.

China's line

Meanwhile, China's Xi has adopted a somewhat softer public line that some are describing as "vaccine diplomacy."

Xi says China will spend $2 billion to help developing countries. China also is among dozens of countries that have signed on to a resolution by member states of the World Health Organization that says a vaccine should be treated as a "global public good" to be distributed widely, fairly and cheaply.

China faced global condemnation for its early efforts to downplay the severity of the virus and has sought to rewrite the narrative by promoting its efforts to find a vaccine and assist other countries.

China is making a major push to develop a vaccine at home and has at least four trials underway.

Xi wants China to be a world leader in the most important technologies of the 21st century, including biopharmaceuticals. If China became the first to develop a vaccine, it would consider it a huge victory.

However, some U.S. national security officials say the Chinese efforts include attempts to hack into American and other Western drug companies to steal valuable research information.

"We have the full expectation that China will do everything in their power to obtain any viable research that we are conducting here in the U.S.," said Bill Evanina, the director of the National Counterintelligence and Security Center. "That will be in line with their capabilities and intent the last decade plus, and we are expecting them to continue to do so."

Global pandemic, global solution

While one country, or one company, may take the lead when it comes to a vaccine, the worldwide nature of the problem points to the need for a truly global solution, according to those in the international health community.

For example, AstraZeneca, which is getting the U.S. government funding, is a Swedish-British firm, which is hoping to produce vaccines based on promising research conducted at Oxford University in Britain. AstraZeneca, like all the major Western pharmaceutical companies, has offices and manufacturing plants spread around the globe.

Many players in many countries are likely to be involved. But it takes time to ramp up vaccine production, and this points to a crucial question: In a world of more than 7 billion people, who's at the front of the line, and who's at the back?

"The challenge is going to come in the first year in terms of capacity, combined with disagreements about who should be first, second and third in line," said Nancy Kass, professor of bioethics and public health at Johns Hopkins University.

New drugs and vaccines traditionally go first to the wealthiest countries, and that's the expectation in this case as well. But the exact order could depend on where the vaccine is first developed. The U.S. and China could have very different priorities on how to distribute a vaccine.

Pharmacist Michael Witte (left) gives Neal Browning a shot in the first-stage study of a potential coronavirus vaccine on March 16 in Seattle. Countries and companies are racing to find a vaccine with some describing the competition as "vaccine nationalism."
Ted S. Warren / AP

Rich countries have been hit hardest by the virus so far. But in many of these nations, COVID-19 cases are leveling off or declining, while they are rising rapidly in the developing world, including countries such as India, Brazil and Peru.

Assessing needs

Global health organizations are working on plans with a focus on poorer nations.

Kate Elder of Doctors Without Borders says her organization often faces challenges in dealing with Western pharmaceutical companies that have tremendous leverage because they are the only one, or one of just a few, that make a critical drug.

"We can design things as a global community," she said. "But ultimately, since the power is in the pharmaceutical corporation's hands to make those decisions, it's up to them. At what scale they produce these vaccines, at what price they set them, and who are the first customers that they'll cater to."

Because the demand for a new vaccine will be so great, nations, political leaders and drug companies are likely to face a range of conflicting pressures. They will need to provide the vaccine at home but will also face intense scrutiny to share it widely, fairly and cheaply abroad.

"It's set up to be a massive geopolitical battle," said Bremmer, of the Eurasia Group. "Not just around the discovery of the vaccine, but the manufacturing chain — with billions of doses needed, and the challenges of a global vaccination campaign."

Greg Myre is an NPR national security correspondent. Follow him @gregmyre1.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

Let's think for a moment about when a coronavirus vaccine becomes available. Which countries are going to be at the front of the line to receive it and which ones are going to be at the back? Global health organizations are working on plans for international cooperation. But there are also signs of competition, a battle between nations that's being described as a kind of vaccine nationalism. Let's talk about this with NPR national security correspondent Greg Myre. Hi, Greg.

GREG MYRE, BYLINE: Good morning, David.

GREENE: So are there certain countries we're talking about here that are already showing signs that they're competing?

MYRE: Yeah. Really, the main competition is between the U.S. and China. Both President Trump and China's President Xi Jinping have been hurt politically by their handling of the virus. And they would love to reverse that by handling the vaccine well at home.

Now, their approaches have been a little bit different. In the U.S., Trump's Operation Warp Speed is designed to get a COVID vaccine for Americans. It's in line with his America first ideology. And it could be a huge boost if it happens before the November election, although that's very, very optimistic. And you've also seen Trump become increasingly critical of China.

GREENE: Well, what is China's position in all this?

MYRE: So President Xi has taken a bit of a softer line, at least publicly. You could, perhaps, call it vaccine diplomacy. China's offering $2 billion to help developing countries deal with the pandemic. China also signed onto a World Health Organization resolution that calls the vaccine to be a global public good. And the U.S. has pointedly not joined in. But China is pushing very hard for a vaccine. It has several trials underway. And, you know, what if China gets a vaccine first? It could have very different priorities about how to distribute it to the rest of the world.

GREENE: I mean, Greg, I just think about this, country's rushing to get it first. But this is a global pandemic. Even if there are politics playing some role here in leaders' minds, isn't there a recognition that this all requires, like, a global solution.

MYRE: Yes, absolutely. Just consider this one example. Oxford University in Britain is working on a vaccine trial that looks pretty promising. They've partnered with AstraZeneca, which is a Swedish-British, multinational drug company. And the U.S. government has announced that it's providing more than a billion dollars to AstraZeneca to make vaccines. So there's going to be a lot of international players. But it does take time to ramp up production. And I spoke about this with Nancy Kass, a professor of bioethics and public health at Johns Hopkins University.

NANCY KASS: The challenge is going to come in what will be, at least, the first year, in terms of capacity combined with disagreements about who should be first, second and third in line.

GREENE: When it comes to who should be first, second and third, Greg, I mean, is the wealth gap in the world going to play a role? I mean, are we going to expect wealthy countries to be able to be at the front and developing countries, you know, some of which have seen rising cases, really struggle?

MYRE: Well, that's probably going to happen, it always does. But global health organizations say this is a recurring challenge in dealing with Western pharmaceutical companies, which have tremendous leverage in the developing world. And I spoke about this with Kate Elder of Doctors Without Borders.

KATE ELDER: We can design things as a global community. But ultimately, since the power is in the pharmaceutical corporations' hands to make those decisions, it's up to them at what scale they produce these vaccines, at what price they set them at and who are the first customers, so to speak, that they'll cater to.

MYRE: So there will be is intense scrutiny on whoever gets a vaccine to share it widely, fairly and a reasonable price. We'll see if that happens.

GREENE: NPR's Greg Myre. Greg, thanks so much.

MYRE: My pleasure. Transcript provided by NPR, Copyright NPR.